Abstract
A vital dye exclusion method following a 4 day tumor sensitivity assay was used to predict clinical response to chemotherapeutics in 16 patients with acute nonlymphoblastic leukemia (n = 12), acute lymphoblastic leukemia (n = 2), diffuse poorly differentiated lymphoma (n = 1) and oat cell carcinoma (n = 1). After 4 days of incubation, controls and drug-supplied cells were stained with fast green and hematoxylin-eosin. A tumor cell survival of 30% was used to distinguishin vitro resistance andin vitro sensitivity. Eight patients responded and five did not respond to the chemotherapy protocol. This agreed with thein vitro results. Two patients who were sensitivein vitro responded only partiallyin vivo but two additional patients sensitivein vitro did not respond. These results indicate that this short-term method may give a simple estimation of drug resistance.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Black M M, Speer F D: Further observations on the effects of cancer therapeutic agents on thein vitro dehydrogenase activity of cancer tissue.J natn Cancer Inst 14, 1147 (1954).
Kaltenbach J P, Kalthenbach M H, Lyons W B: Nigrosin as a dye in differentiating live and dead ascites cells.Exp Cell Res 15, 112 (1958).
Hamburger A W: Use ofin vitro tests in predictive chemotherapy.J natn Cancer Inst 66, 981 (1981).
Salmon S E, Hamburger A W, Soehlen B, Durie B G M, Albert D S, Moon T E: Quantitation of differential sensitivity of human stem cells to anticancer drugs.New Engl J Med 298, 1321 (1978).
Sondak V K, Bertelsen C A, Tanigawa Net al: Clinical correlations with chemosensitivities measured in rapid incorporation assay.Cancer Res 44, 1725 (1984).
Selby P, Buick R N, Tannock I: A critical appraisal of the “Human tumor stem-cell assay”.New Engl J Med 308, 129 (1983).
Von Hoff D D: Send this patient’s tumor for culture and sensitivity.New Engl J Med 308, 154 (1983).
Dow L W, Dahl G V, Kalwinsky D K, Mirro J, Nash M B, Roberson P K: Correlation of drug sensitivityin vitro with clinical responses in childhood acute myeloid leukemia.Blood 68, 400 (1986).
Weisenthal L M, Marsden J A, Dill P L, Macaluso C K: A novel dye exclusion method for testingin vitro chemosensitivity of human tumors.Cancer Res 43, 749 (1983).
Bosanquet A G, Bird M C, Price W J P, Gilby E D: An assessment of a short-term tumor chemosensitivity assay in chronic lymphocytic leukemia.Br J Cancer 47, 781 (1983).
Nagourney R A, Jacobson R J, Wooley P V: Accurate prediction of response to treatment in human leukemia utilizing a vital-dye exclusion chemosensitivity technique.Proc Am Soc clin Oncol 3, 203 (1984).
Friedenberg W R, Baldauf M C, Marx J J Jr, Siemers R F: A dye exclusion assay to determinein vitro chemosensitivity in patients with chronic lymphocytic leukemia.Proc Am Soc clin Oncol 5, 152 (1986).
Morgan D, Freshney R I, Darling J L, Thomas D G, Celik F: Assay of anticancer drugs in tissue culture: cell cultures of biopsies from human astrocytoma.Br J Cancer 47, 205 (1983).
White R J, Durr F E: Development of mitoxantrone.Invest New Drugs 3, 85 (1985).
Chan C, Knight N, Schechter G: Lack ofin vitro differentiating effect of low dose Ara-C in human leukemic cells.Proc Am Soc clin Oncol 5, 41 (1986).
Mattern J, Kaufmann M, Wayss K, Volm M: Studies in the drug sensitivity of short-term cultured tumor cell suspensions, in:Human Tumors in Short-Term Culture, p. 301. London, Academic Press (1976).
Weisenthal L M, Lippman M E: Clonogenic and nonclonogenicin vitro chemosensitivity assays.Cancer Treat Rep 69, 615 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Beksac, M., Kansu, E., Kars, A. et al. A rapid drug sensitivity assay for neoplasmatic cells. Med. Oncol. & Tumor Pharmacother. 5, 253–257 (1988). https://doi.org/10.1007/BF03003193
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF03003193